SCHEMBL4075468

SCHEMBL4075468

Cc1ccccc1-c1cc2ncnc(NCCc3c(C)[nH]c4c(F)ccc(C)c34)c2s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
PIP4K2A P48426 5/20 0.38
PIP4K2C Q8TBX8 5/20 0.38
TYK2 P29597 1/20 0.38
FLT1 P17948 6/20 0.38
EGFR P00533 3/20 0.38
KDR P35968 1/20 0.36
CYP1A2 P05177 5/20 0.35
CYP3A4 P08684 5/20 0.35
CYP2D6 P10635 5/20 0.35
ALDH1A1 P00352 4/20 0.35
TSHR P16473 4/20 0.35
CLK4 Q9HAZ1 4/20 0.35
CYP2C19 P33261 4/20 0.35
MAPK1 P28482 3/20 0.35
HSD17B10 Q99714 3/20 0.35
ALOX15 P16050 2/20 0.35
STK17B O94768 1/20 0.35
USP2 O75604 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4077908 0.96 STK17B (0.40) NPC1RAB9APIP4K2APIP4K2CTYK2
SCHEMBL4070509 0.95 NPC1 (0.37) NPC1RAB9APIP4K2APIP4K2CTYK2
SCHEMBL3939316 0.92 NPC1 (0.39) NPC1RAB9APIP4K2APIP4K2CTYK2
SCHEMBL4071195 0.92 FLT1 (0.46) NPC1RAB9ATYK2FLT1EGFR
SCHEMBL4068191 0.92 FLT1 (0.38) NPC1RAB9APIP4K2APIP4K2CTYK2
SCHEMBL4065656 0.90 FLT1 (0.45) NPC1RAB9ATYK2FLT1EGFR
SCHEMBL3936999 0.90 NPC1 (0.42) NPC1RAB9APIP4K2APIP4K2CTYK2
SCHEMBL4073363 0.90 NPC1 (0.43) NPC1RAB9APIP4K2APIP4K2CTYK2
SCHEMBL3936128 0.90 NPC1 (0.43) NPC1RAB9APIP4K2APIP4K2CTYK2
SCHEMBL4073421 0.90 EGFR (0.37) NPC1RAB9APIP4K2APIP4K2CTYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007421-A1 INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor PTGER2, PTGER1, PTGDR2 NPC1 2246/4885RAB9A 3318/4885PIP4K2A 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.